CVS Adds Lilly's Zepbound To Preferred Drug List In Reversal

CVS Adds Lilly's Zepbound To Preferred Drug List In Reversal

• CVS Health (NYSE: CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members— including the reintroduction of Zepbound® (tirzepatide) as a covered medication. These changes build on Caremark's industry leading efforts as a pharmacy benefits manager to explore all potential avenues that help patients get FDA-approved weight management medications at an affordable cost. Plan sponsors that adopt CVS Caremark template formularies retain discretion to customize coverage for their members.

You May Also Be Interested In

• Fortitude and HeartSciences agree to all-stock merger deal
• GCT Semiconductor shifts strategic focus toward AI edge connectivity
• Oman, Iran To Work On Agreement On Management Of Navigation